Peptune Tirzepatide
A dual GIP and GLP-1 receptor agonist, studied as a reference compound in incretin research.
$159.99
In stock
- Class
- Peptide analogue
- Amount per vial
- 30 mg
- Form
- Lyophilized powder
- Length
- 39 residues
- CAS number
- 2023788-19-2
- Molecular weight
- 4,813.5 g/mol
- Appearance
- White powder
For laboratory research use only · Certificate of analysis · Full specifications
Documentation
Certificate of analysis
No certificate is published for this product yet. Contact us to check the documentation for the current batch before you order; published certificates are listed in the documentation library.
Overview
About this product
Tirzepatide is a 39-residue synthetic peptide that activates two incretin receptors, the GIP receptor and the GLP-1 receptor. It is acylated with a C20 fatty diacid chain that binds albumin, which lengthens its half-life in research models. Its receptor pharmacology, including a stronger preference for the GIP receptor than for GLP-1R, is well characterised, which makes it a common reference point in incretin studies. It is often compared with single-receptor GLP-1 agonists and with the triple agonist retatrutide. Supplied as a lyophilized powder in a sealed vial. What the research shows Tirzepatide has been studied in large randomised human trials. In the phase 3 SURMOUNT-1 trial, published in 2022, 2,539 adults with obesity, or overweight with at least one weight-related complication, and without diabetes were assigned to tirzepatide or placebo for 72 weeks; mean weight change was -15.0% to -20.9% across the three tirzepatide groups and -3.1% with placebo. In the 40-week SURPASS-2 trial, published in 2021, 1,879 patients with type 2 diabetes were assigned to tirzepatide or semaglutide; glycated haemoglobin changed by -2.01 to -2.30 percentage points with tirzepatide and -1.86 with semaglutide. In both trials the most common adverse events were gastrointestinal. Sources: Jastreboff et al., New England Journal of Medicine, 2022, PMID 35658024. Frías et al., New England Journal of Medicine, 2021, PMID 34170647. For laboratory research use only. Not for human or veterinary use. Purity and identity are stated on the batch certificate, published on this page once it is on file.
Research profile
Tirzepatide in the literature
Research areas · 0–5
The molecule
About this compound
Tirzepatide is a synthetic peptide of 39 amino acids. In the published literature it is also identified as LY3298176, and it is described as engaging the GIP and GLP-1 receptors. A C20 fatty diacid is part of that published structure. It comes in 10 mg, 20 mg and 30 mg vials, and the figure on the label is the contents of the vial.
- Class
- Peptide analogue
- CAS number
- 2023788-19-2
- Length
- 39 residues
- Molecular formula
- C225H348N48O68
- Molecular weight
- 4,813.5 g/mol
- Target in the literature
- GIP and GLP-1 receptor agonist
- Half-life (published)
- About 5 days in people (phase 1, PMID 34647404)
- Form
- Lyophilized powder
- Amount per vial
- 30 mg
- Appearance
- White powder
- Solubility
- Sterile water or bacteriostatic water
- Storage (unopened)
- −20 °C long term, 2 to 8 °C short term; sealed and away from light
- Storage (in solution)
- 2 to 8 °C, away from light; do not freeze
- Packaging
- Sealed vial
- Notes
- Literature code: LY3298176
- Receptors named in the literature: GIP and GLP-1
Published research
These are published papers about the molecule. A paper is not a dose, not medical advice, and not evidence that this vial is for human or veterinary use.
- Tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI).
The Lancet Diabetes & Endocrinology · 2022 · PMID 35468325
A magnetic-resonance substudy of a clinical trial. Not a dose and not evidence that this research vial is a medicine.
- Tirzepatide for Obesity Treatment and Diabetes Prevention.
New England Journal of Medicine · 2025 · PMID 39536238
A clinical trial of the molecule. The title is the paper's subject. It is not a claim about this vial.
For laboratory research use only. Not for human or veterinary use. The amount on the label is the contents of the vial, not a dose.
Ordering in Canada
Buying Peptune Tirzepatide in Canada
- Can I buy Peptune Tirzepatide in Canada?
- Yes. Peptune sells Peptune Tirzepatide online for laboratory research use only, with tracked delivery to every province and territory in Canada.
- How much is Peptune Tirzepatide?
- 20 mg: $139; 10 mg: $75; 30 mg: $159.99, in Canadian dollars. Free shipping on orders of $150 or more.
- Is there a certificate of analysis for Peptune Tirzepatide?
- The certificate of analysis for the current batch of Peptune Tirzepatide is published on this page and in the COA library as soon as it is on file.
- How is Peptune Tirzepatide supplied?
- As a lyophilized powder in a sealed vial, labelled with the compound and the amount: 30 mg. The amount is the contents of the vial, not a dose. Keep it sealed, dry, cold and away from light.
- How do I pay?
- By Interac e-Transfer or crypto. The payment instructions arrive by email after you place the order, and nothing is charged before that step.
Verified buyers
Reviews
No reviews yet. Reviews come from verified buyers only, and each one is checked before it appears.
Bought this? Write a review
Loading…
